Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,801.13 -1,337.15 (-2.15%) CMC Crypto 200
1,260.53 -97.48 (-7.17%)
Merck & Co., Inc. (MRK)
| Previous close | 130.23 |
| Open | 130.82 |
| Bid | 130.29 x 800 |
| Ask | 130.30 x 800 |
| Day's range | 130.10 - 130.88 |
| 52-week range | 99.14 - 133.10 |
| Volume | |
| Avg. volume | 8,207,993 |
| Market cap | 330.405B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 144.94 |
| EPS (TTM) | 0.90 |
| Earnings date | 30 Jul 2024 |
| Forward dividend & yield | 3.08 (2.37%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 131.59 |
Simply Wall St.Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...
ZacksInvestors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
CNW GroupHealth Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with gemcitabine-based chemotherapy, for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma (BTC). This approval is based on the results from the Phase 3 KEYNOTE-966 trial, which demonstrated a statistically significant and clinically meaningful improvem
